Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Bevacizumab for the Treatment of Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer

NCT07009145 is registered in ClinicalTrials.gov with Qianfoshan Hospital as lead sponsor.

NCT NCT07009145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07009145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Bevacizumab for the Treatment of Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer
Lead sponsor
Qianfoshan Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 27, 2025
Completion date
December 31, 2027
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer (crc), msi-h/dmmr colorectal cancer, unresectable colorectal cancer